Shanghai MicroPort HeartTech Enters into 2024 Kewei Distribution Framework Agreement and Provides RMB 10 Million Loan

Zhitong Finance APP reported that Heartflow Medical-B (02160) announced that, on July 19, 2024 (after trading hours), Shanghai MicroPort CardioFlow and Kewei Medical entered into the 2024 Kewei Distribution Framework Agreement. According to the agreement, Kewei Medical agreed to grant Shanghai MicroPort CardioFlow the exclusive right to distribute the products in China, for a term starting from July 19, 2024, to December 31, 2025 (inclusive of both start and end dates).

On July 19, 2024 (after trading hours), Shanghai MicroPort CardioFlow and Kewei Medical entered into the Kewei Loan Agreement, under which Shanghai MicroPort CardioFlow (as the lender) agreed to grant a loan facility of RMB 10 million to Kewei Medical (as the borrower) at an interest rate equivalent to the one-year LPR on the date of the Kewei Loan Agreement. The loan facility will be secured by a guarantee from Kewei Medical in favor of Shanghai MicroPort CardioFlow, with certain equipment and facilities of Kewei Medical (with a total net value of approximately RMB 17.1 million) as collateral.